0001104659-21-030840.txt : 20210302 0001104659-21-030840.hdr.sgml : 20210302 20210302170655 ACCESSION NUMBER: 0001104659-21-030840 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210302 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210302 DATE AS OF CHANGE: 20210302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANTEL MEDICAL CORP CENTRAL INDEX KEY: 0000019446 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 221760285 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31337 FILM NUMBER: 21704971 BUSINESS ADDRESS: STREET 1: OVERLOOK AT GREAT NOTCH STREET 2: 150 CLOVE ROAD CITY: LITTLE FALLS STATE: NJ ZIP: 07424 BUSINESS PHONE: 973-890-7220 MAIL ADDRESS: STREET 1: OVERLOOK AT GREAT NOTCH STREET 2: 150 CLOVE ROAD CITY: LITTLE FALLS STATE: NJ ZIP: 07424 FORMER COMPANY: FORMER CONFORMED NAME: CANTEL INDUSTRIES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STENDIG INDUSTRIES INC DATE OF NAME CHANGE: 19890425 FORMER COMPANY: FORMER CONFORMED NAME: CHARVOZ CARSEN CORP DATE OF NAME CHANGE: 19861215 8-K 1 tm218182d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 Or 15(d) of The Securities Exchange Act of 1934

Date of earliest event reported: March 2, 2021

CANTEL MEDICAL CORP.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-31337

22-1760285

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

150 Clove Road, Little Falls, New Jersey

07424

(973) 890-7220

(Address of Principal Executive Offices)

(Zip code)

(Registrant’s telephone number,

including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

x	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Common Stock

CMD

New York Stock Exchange

(Title of each class)

(Trading Symbol)

(Name of each exchange on which

registered)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Explanatory Note

This Current Report on Form 8-K is being filed by Cantel Medical Corp. (the “Company”) for the purpose of incorporating it by reference into the registration statement on Form S-4 to be filed by STERIS plc (“STERIS”), as it may be amended or supplemented, in connection with the pending merger transaction between the Company and STERIS.

Important Information for Investors and Shareholders

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed merger between STERIS and Cantel, STERIS will file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that will include a proxy statement of Cantel that also constitutes a prospectus of STERIS. The definitive proxy statement/prospectus will be delivered to shareholders of Cantel. INVESTORS AND SECURITY HOLDERS OF STERIS AND CANTEL ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the definitive proxy statement/prospectus (when available) and other documents filed with the SEC by STERIS and Cantel through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by STERIS will be available free of charge on STERIS’s internet website at www.STERIS.com or by contacting STERIS’s Investor Relations Department at (440) 392-7245. Copies of the documents filed with the SEC by Cantel will be available free of charge on Cantel’s internet website at www.cantelmedical.com or by contacting Cantel’s Investor Relations Department at (763) 553-3341.

Participants in the Merger Solicitation

STERIS, Cantel, their respective directors and certain of their respective executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Cantel shareholders in connection with the proposed merger will be set forth in the proxy statement/prospectus when it is filed with the SEC. Information about the directors and executive officers of Cantel is set forth in its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on November 18, 2020 and certain of its Current Reports on Form 8-K. Information about the directors and executive officers of STERIS is set forth in its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on June 5, 2020 and certain of its Current Reports on Form 8-K. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus filed with the above-referenced registration statement on Form S-4 and other relevant materials to be filed with the SEC when they become available.

Item 9.01. Financial Statements and Exhibits

(a) Financial Statements of Business to be Acquired.

The unaudited condensed consolidated financial statements of Dental Holding, LLC and Subsidiaries as of September 30, 2019, and for the nine months ended September 30, 2019 and 2018 and the notes related thereto, are filed as Exhibit 99.1 hereto.

(b) Exhibits.

Exhibit No.		Description of Exhibit

99.1		Unaudited condensed consolidated financial statements of Dental Holding, LLC and Subsidiaries as of September 30, 2019 and for the nine months ending September 30, 2019 and 2018, and the notes related thereto.

104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CANTEL MEDICAL CORP.
	(Registrant)


Date: March 2, 2021	By:	/s/ Brian R. Capone
		Brian R. Capone
		Senior Vice President, Corporate Controller and Chief Accounting Officer

EX-99.1 2 tm218182d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Dental Holding, LLC

and Subsidiaries

Condensed Consolidated Financial Report

September 30, 2019

Contents

Financial statements

Unaudited condensed consolidated balance sheets	1

Unaudited condensed consolidated statements of income	2

Unaudited condensed consolidated statements of comprehensive income	3

Unaudited condensed consolidated statements of members’ equity	4

Unaudited condensed consolidated statements of cash flows	5-6

Notes to unaudited condensed consolidated financial statements	7-15

Dental Holding, LLC and Subsidiaries

Unaudited Condensed Consolidated Balance Sheets

September 30, 2019 and December 31, 2018

(Dollars in Thousands)

	September 30,		December 31,
	2019		2018
Assets
Current assets:
Cash and cash equivalents	$	8,889	$	5,622
Account receivables, net		25,786		28,265
Other receivables		8,151		1,744
Inventories, net		49,379		46,233
Prepaid expenses and other current assets		3,783		3,393
Total current assets		95,988		85,257
Property and equipment, net		31,472		30,321
Other assets:
Intangible assets, net		6,108		7,019
Goodwill		20,573		20,588
Other		50		85
		26,731		27,692
	$	154,191	$	143,270
Liabilities and Members' Equity
Current liabilities:
Current portion of long-term debt	$	6,250	$	-
Accounts payable		4,563		6,983
Accrued compensation		9,889		11,201
Accrued expenses		4,794		4,873
Accrued state, foreign and sales taxes		2,781		2,328
Total current liabilities		28,277		25,385
Noncurrent liabilities:
Line of credit		12,000		-
Long-term debt, less current maturities		89,671		-
Capital lease obligations, less current maturities		4,339		4,629
Deferred compensation		530		1,978
Other		576		641
		107,116		7,248
Commitments (Note 11)
Members' equity		18,798		110,637
	$	154,191	$	143,270

See notes to unaudited condensed consolidated financial statements.

1

Dental Holding, LLC and Subsidiaries

Unaudited Condensed Consolidated Statements of Income

Nine-Month Periods Ended September 30, 2019 and 2018

(Dollars in Thousands)

	2019			2018
Net sales	$	160,947		$	148,124
Cost of goods sold		61,480			55,292
Gross profit		99,467			92,832
Selling, general and administrative expenses		73,147			71,223
Income from operations		26,320			21,609
Other income (expense):
Interest expense, net		(4,782	)		(814	)
Foreign exchange gain		287			160
Other, net		(61	)		47
		(4,556	)		(607	)
Income before income taxes		21,764			21,002
Income tax expense		1,101			1,158
Net income	$	20,663		$	19,844

See notes to unaudited condensed consolidated financial statements.

2

Dental Holding, LLC and Subsidiaries

Unaudited Condensed Consolidated Statements of Comprehensive Income
Nine-Month Periods Ended September 30, 2019 and 2018
(Dollars in Thousands)

	2019			2018
Net income	$	20,663		$	19,844
Other comprehensive loss:
Foreign currency translation adjustment		(696	)		(1,664	)
Comprehensive income	$	19,967		$	18,180

See notes to unaudited condensed consolidated financial statements.

3

Dental Holding, LLC and Subsidiaries

Unaudited Condensed Consolidated Statements of Members' Equity

Nine-Month Periods Ended September 30, 2019 and 2018

(Dollars in Thousands)

				Accumulated
	Undistributed			Other			Total
	Members'			Comprehensive			Members'
	Equity			Income (Loss)			Equity
Balance, January 1, 2018	$	95,217		$	187		$	95,404
Distributions		(7,661	)		-			(7,661	)
Net income		19,844			-			19,844
Other comprehensive loss		-			(1,664	)		(1,664	)
Equity-based compensation		206			-			206
Balance, September 30, 2018	$	107,606		$	(1,477	)	$	106,129
Balance, January 1, 2019	$	111,449		$	(812	)	$	110,637
Distributions		(111,806	)		-			(111,806	)
Net income		20,663			-			20,663
Other comprehensive loss		-			(696	)		(696	)
Balance, September 30, 2019	$	20,306		$	(1,508	)	$	18,798

See notes to unaudited condensed consolidated financial statements.

4

Dental Holding, LLC and Subsidiaries

Unaudited Condensed Consolidated Statements of Cash Flows

Nine-Month Periods Ended September 30, 2019 and 2018

(Dollars in Thousands)

	2019			2018
Cash flows from operating activities:
Net income	$	20,663		$	19,844
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		4,445			3,616
Allowance for doubtful accounts		(51	)		(134	)
Deferred compensation		772			465
Stock-based compensation		-			206
Changes in operating assets and liabilities:
Accounts receivable		2,113			6,860
Other receivables		(6,414	)		(934	)
Inventories		(3,379	)		(7,318	)
Prepaid expenses and other assets		(420	)		(262	)
Accounts payable		(2,399	)		(1,517	)
Accrued compensation		(1,414	)		(3,331	)
Accrued expenses and other liabilities		(132	)		(462	)
Income taxes payable		817			584
Deferred compensation payments		(2,228	)		-
Net cash provided by operating activities		12,373			17,617
Cash flows from investing activities:
Purchases of property and equipment		(4,729	)		(4,051	)
Purchase of CHIPS		-			(19,300	)
Net cash used in investing activities		(4,729	)		(23,351	)
Cash flows from financing activities:
Borrowings on line of credit		58,634			12,774
Payments on line of credit		(46,634	)		(7,347	)
Checks in excess of bank balances		-			3,145
Borrowings on long-term debt		100,000			-
Repayments on long-term debt		(3,750	)		-
Payment of deferred financing costs		(387	)		-
Distributions paid		(111,806	)		(7,661	)
Payment on related party capital lease obligations		(190	)		(147	)
Net cash (used in) provided by financing activities		(4,133	)		764
Effect of exchange rates on cash		(244	)		(1,505	)
Net increase (decrease) in cash and cash equivalents		3,267			(6,475	)
Cash and cash equivalents:
Beginning of period		5,622			10,881
End of period	$	8,889		$	4,406

(Continued)

5

Dental Holding, LLC and Subsidiaries

Unaudited Consolidated Statements of Cash Flows (Continued)

Nine-Month Periods Ended September 30, 2019 and 2018

(Dollars in Thousands)

	2019		2018
Supplemental disclosures of cash flow information:
Interest paid	$	4,805	$	424
Income taxes paid	$	576	$	1,071
Supplemental schedules of noncash investing and financing activities:
Acquisition of business:
Assets acquired			$	19,739
Liabilities assumed				-
Net assets acquired				19,739
Less: Seller note				(439	)
			$	19,300

See notes to unaudited condensed consolidated financial statements.

6

Dental Holding, LLC and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Dollars in Thousands except Share and per Share information)

Note 1. Nature of Business and Significant Accounting Policies

Basis of presentation: The unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of interim financial reporting. Therefore, certain information and disclosures normally included in financial statements and related notes prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s December 31, 2018 consolidated financial statements. In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring unaudited adjustments) considered necessary for a fair presentation of the Company’s unaudited condensed consolidated balance sheets as of September 30, 2019, and the unaudited condensed consolidated statements of income for the nine-months ended September 30, 2019 and 2018.

Foreign financial concentration: Assets located outside the United States of America (U.S.) were approximately 15% of total assets as of September 30, 2019. Sales to customers located outside of the U.S. approximated 26% and 28% of net sales for the nine-month periods ended September 30, 2019 and 2018, respectively. Net income attributable to foreign operations approximated $3,118 and $3,821 for the nine-month periods ended September 30, 2019 and 2018, respectively.

Customer concentration: Sales to two customers for the nine-month period ended September 30, 2019, approximated $38,273 (related party - parent company of Hurley Healthcare Corp. (HHC), see Notes 7 and 12) and $19,554, and comprised 36% of net sales. Accounts receivable from such customers approximated $5,830 (related party - parent company of HHC) and $1,814, respectively, and comprised 29% of accounts receivable at September 30, 2019. Sales to two customers for the nine-month period ended September 30, 2018, approximated $34,105 (related party - parent company of Hurley Healthcare Corp. (HHC), see Notes 7 and 12) and $18,234, and comprised 35% of net sales.

The Company typically has higher revenues with customers in the second half of their calendar year.

Accounts receivable: Accounts receivable are stated net of allowances of approximately $852 at September 30, 2019 and $860 at December 31, 2018.

Impairment of long-lived assets: There was no impairment of long-lived assets for the nine-month periods ended September 30, 2019 or 2018.

7

Dental Holding, LLC and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Dollars in Thousands except Share and per Share information)

Note 1. Nature of Business and Significant Accounting Policies (Continued)

Goodwill: There was no impairment of goodwill for the nine-month periods ended September 30, 2019 or 2018.

Intangible assets: There was no impairment of intangible assets for the nine-month periods ended September 30, 2019 or 2018.

Foreign currency: Transaction gains and losses are included in the unaudited condensed consolidated statements of income as a component of other expenses, with net gains approximating $287 and $160 for the nine-month periods ended September 30, 2019 and 2018, respectively.

Self-insurance: Accruals for reported claims and claims incurred but not reported (IBNR) are based on all relevant data, including statistical data and historical experience, and approximated $499 at September 30, 2019 and $547 at December 31, 2018.

Advertising: Advertising expenses approximated $4,288 and $4,806 for the nine-month periods ended September 30, 2019 and 2018, respectively.

Product development: Product development costs approximated $1,084 and $1,092 for the nine-month periods ended September 30, 2019 and 2018, respectively.

Shipping revenue and costs: Direct costs associated with the shipment of products, which approximated $1,450 and $1,431 for the nine-month periods ended September 30, 2019 and 2018, respectively, are included as a component of selling, general and administrative expenses.

Recent accounting pronouncements: In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a full retrospective or retrospective with cumulative effect transition method.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The guidance in this ASU and its subsequently issued amendments supersedes the leasing guidance in Topic 840, Leases. Under the new guidance, lessees are required to recognize lease assets and lease liabilities on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required. An entity may adopt the guidance either (1) retrospectively to each prior reporting period presented in the financial statements with a cumulative-effect adjustment recognized at the beginning of the earliest comparative period presented or (2) retrospectively at the beginning of the period of adoption through a cumulative-effect adjustment.

8

Dental Holding, LLC and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Dollars in Thousands except Share and per Share information)

Note 1. Nature of Business and Significant Accounting Policies (Continued)

Due to the sale transaction disclosed in Note 13, the Company’s wholly owned subsidiaries applied ASU 2014-09 and ASU 2016-02 in accordance with Cantel Medical Corp.’s accounting policies after the sale by Dental Holding, LLC.

In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The ASU simplifies the measurement of goodwill impairment by eliminating the requirement that an entity compute the implied fair value of goodwill based on the fair values of its assets and liabilities to measure impairment. Instead, goodwill impairment will be measured as the difference between the fair value of the reporting unit and the carrying value of the reporting unit. The ASU also clarifies the treatment of the income tax effect of tax deductible goodwill when measuring goodwill impairment loss. ASU 2017-04 will be effective for the Company beginning on January 1, 2022. ASU 2017-04 must be applied prospectively with early adoption permitted. The Company is currently evaluating the impact of the adoption of this guidance on its unaudited condensed consolidated financial statements.

Subsequent events: The Company has evaluated subsequent events for potential recognition and/or disclosure through February 24, 2021, the date the unaudited condensed consolidated financial statements were available to be issued.

9

Dental Holding, LLC and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Dollars in Thousands except Share and per Share information)

Note 2. Inventories

Inventories at September 30, 2019 and December 31, 2018, consist of the following:

	September 30,			December 31,
	2019			2018
Raw materials	$	4,219		$	3,857
Work in process		2,855			2,476
Finished goods - manufactured		30,308			31,338
Finished goods - purchased		12,929			9,527
Total		50,311			47,198
Less allowance for reduction to net realizable value		(932	)		(965	)
Inventories	$	49,379		$	46,233

Inventories on a LIFO basis are equivalent to inventories on a FIFO basis as of September 30, 2019 and December 31, 2018.

Note 3. Property and Equipment

Depreciation and amortization of property and equipment totaled approximately $3,557 and $2,762 for the nine-month periods ended September 30, 2019 and 2018, respectively.

Estimated additional costs to complete projects included in construction in progress approximated $5,144 at September 30, 2019 and $2,709 at December 31, 2018.

Note 4. Intangible Assets

Amortization expense totaled approximately $888 and $856 for the nine-month periods ended September 30, 2019 and 2018, respectively.

Note 5. Goodwill

The following table represents the balance and changes in goodwill as of September 30, 2019 and September 30, 2018:

Balance as of January 1, 2018	$	9,495
Foreign currency effect		80
Goodwill related to the acquisition of Chips		11,114
Balance as of September 30, 2018	$	20,689
Balance as of January 1, 2019	$	20,588
Foreign currency effect		(15	)
Balance as of September 30, 2019	$	20,573

10

Dental Holding, LLC and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Dollars in Thousands except Share and per Share information)

Note 5. Goodwill (Continued)

On August 31, 2018, the Company acquired, for cash and a seller note, certain assets and operations of Chips Manufacturing, Inc. (Chips). Chips is engaged primarily in the precision machining for medical and dental products and other material and was a supplier of parts to the Company.

11

Dental Holding, LLC and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Dollars in Thousands except Share and per Share information)

Note 6. Line of Credit and Long-Term Debt

On January 15, 2019, the Company entered into a new credit agreement which provided for a revolving line of credit of $30,000 and a term loan of $100,000, both with a maturity date of January 15, 2024. The term loan requires quarterly principal payments ranging from $1,250 to $2,500 through maturity. Interest on the outstanding loans is based on either prime (with a floor based on one month LIBOR plus 2.5%) or LIBOR, plus a spread based on leverage. The loans are subject to fixed charge and total leverage ratio financial covenants. The loans are secured by substantially all assets in the United States. $12,000 is outstanding on the line of credit at September 30, 2019. The Company used the borrowings on the term loan to pay distributions to the Class A unit holders in the amount of $100,000.

Maturities of long-term debt as of September 30, 2019, net of deferred financing costs of $329 are as follows:

Years ending December 31:
October 1, 2019 - December 31, 2019	$	1,250
2020		7,500
2021		10,000
2022		10,000
2023		10,000
Thereafter		57,500
	$	96,250

Note 7. Members’ Equity

On January 14, 2019, the option holder (Note 8) exercised his options to purchase 700,000 Class A units from HHC. As a result of this exercise, HHC’s ownership of Class A units decreased from 55% to 48%, and the option holder became a 7% owner of the Company’s Class A units. No Class B units are outstanding as of September 30, 2019 or December 31, 2018. As of September 30, 2019 and December 31, 2018, the Company had 10,000,000 Class A units outstanding.

The Company’s amended and restated Operating Agreement provides HHC with a put right, if certain conditions exist, that would require the Company to repurchase all of the outstanding membership units owned by HHC. Additionally the Operating Agreement provides the Company with a call right, if certain conditions exist, that would allow the Company to repurchase all of the outstanding membership units owned by HHC. No conditions exist that would trigger the HHC put right or the Company’s call right as of September 30, 2019.

12

Dental Holding, LLC and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Dollars in Thousands except Share and per Share information)

Note 8. Equity-Based Compensation

Compensation expense for the stock options, recorded on the straight-line method over the vesting period, was $206 for the nine-month period ended September 30, 2018. There was no expense recorded for the nine-month period ended September 30, 2019.

Note 9. Employee Benefit Plan

Company matching contributions approximated $1,245 and $1,035 for the nine-month periods ended September 30, 2019 and 2018, respectively.

13

Dental Holding, LLC and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Dollars in Thousands except Share and per Share information)

Note 10. Deferred Compensation

The Company recognized approximately $780 and $465 for the nine-month periods ended September 30, 2019 and 2018, respectively, related to the deferred compensation plans. During the nine-month period ended September 30, 2019, $2,228 was paid out related to the plan.

Note 11. Commitments and Contingencies

The long-term capital lease obligations are included in noncurrent liabilities and the current portion is included in accrued expenses and are summarized as follows as of September 30, 2019 and December 31, 2018:

	September 30,			December 31,
	2019			2018
Capital lease obligations	$	4,656		$	4,846
Less current portion of capital lease obligations		(317	)		(217	)
	$	4,339		$	4,629

Total rent expense for operating leases approximated $1,245 and $1,199 for the nine-month periods ended September 30, 2019 and 2018, respectively.

Note 12. Related-Party Transactions

Amounts in accrued expenses related to a marketing differential that J&J, a subsidiary of Dental Holding, LLC, owes to the parent company of HHC approximated $242 as of September 30, 2019 and $350 as of December 31, 2018. The Company recognized approximately $229 and $230 of expense for the nine-month periods ended September 30, 2019 and 2018, respectively, related to this agreement.

On July 1, 2010, the Company entered into a preferred vendor agreement with the parent company of HHC. The preferred vendor agreement requires the Company to make marketing support payments of $1,000 per year for three years of the agreement, and $500 per year thereafter until such time that the agreement is terminated by either party (no earlier than June 30, 2020).

During 2018 and 2017, the Company made annual payments of $500 related to the preferred vendor agreement with the parent company of HHC, which are being amortized over the period out of prepaid expenses and other current assets, respectively. The Company recognized $375 of expense for the nine-month periods ended September 30, 2019 and 2018, related to this agreement.

The Company recognized $558 of expense for each of the nine-month periods ended September 30, 2019 and 2018, related to the preferred vendor agreement with HF Illinois.

The Company has a receivable from an employee of the Company for personal expenses in the amount of $112 at September 30, 2019 and $277 at December 31, 2018.

14

Dental Holding, LLC and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Dollars in Thousands except Share and per Share information)

Note 13. Sale Transaction

On October 1, 2019, Dental Holding, LLC sold 100% of its interest in its wholly owned subsidiaries to Cantel Medical Corp. In connection with this transaction, the Company incurred certain costs that were contingent on the transaction closing and therefore not recorded in its statement of income for the period ended September 30, 2019. Included in these costs were bonuses in the amount of $6,556, paid to certain employees on September 30, 2019. The Company borrowed on its line of credit to pay these bonuses. The Company recorded the payment of these bonuses in other receivables on the September 30, 2019 balance sheet. The Company believes that if the transaction had not closed, the payment of these bonuses would have been recaptured. As a result of this transaction, the Company paid off its revolving line of credit and long-term debt, and its credit agreement was terminated.

15

EX-101.SCH 3 cmd-20210302.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cmd-20210302_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cmd-20210302_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm218182d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000019446 2021-03-02 2021-03-02 iso4217:USD shares iso4217:USD shares 0000019446 false 8-K 2021-03-02 CANTEL MEDICAL CORP. DE 001-31337 22-1760285 150 Clove Road Little Falls NJ 07424 973 890-7220 true false false false Common Stock CMD NYSE false XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 02, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 02, 2021
Entity File Number	001-31337
Entity Registrant Name	CANTEL MEDICAL CORP.
Entity Central Index Key	0000019446
Entity Tax Identification Number	22-1760285
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	150 Clove Road
Entity Address, City or Town	Little Falls
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07424
City Area Code	973
Local Phone Number	890-7220
Written Communications	true
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	CMD
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cantelmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm218182d1_8k.htm cmd-20210302.xsd cmd-20210302_lab.xml cmd-20210302_pre.xml tm218182d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm218182d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm218182d1_8k.htm" ] }, "labelLink": { "local": [ "cmd-20210302_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "cmd-20210302_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "cmd-20210302.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cmd", "nsuri": "http://cantelmedical.com/20210302", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm218182d1_8k.htm", "contextRef": "From2021-03-02to2021-03-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://cantelmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm218182d1_8k.htm", "contextRef": "From2021-03-02to2021-03-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cantelmedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-030840-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-030840-xbrl.zip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end